During the past decade, Clarkston Medical Group conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Clarkston Medical Group" are "Acute Gout" (1 trials) and "Type 2 Diabetes Mellitus" (1 trials). Many other conditions were trialed in "Clarkston Medical Group" in a lesser frequency.

Most popular intervention types in "Clarkston Medical Group" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Canakinumab 150 mg" (1 trials), "LCQ908A" (1 trials), "Placebo" (1 trials), "Placebo to canakinumab" (1 trials) and "Placebo to triamcinolone acetonide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Clarkston Medical Group" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Clarkston Medical Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Clarkston Medical Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Clarkston Medical Group, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".